title: Infective complications in renal allograft recipients: epidemiology and outcome.
abstract: BACKGROUND
  Successful renal transplantation strictly depends on good control of rejection and better prevention and treatment of infections, which remain serious threats.
  
  
  METHODS
  This retrospective, observational study of 245 renal allograft recipients who underwent transplantation between January 2002 and December 2005 included a 21+/-10 months follow-up.
  
  
  RESULTS
  A total of 110 (44.9%) patients developed an infective process during the posttransplantation period, namely, 232 infective processes. Eighty patients developed at least 1 episode of urinary tract infection (UTI) 11 patients (4%) had a wound infection, and 30 patients (12%) had pneumonia. We diagnosed 35 cases of bacteremia (35%), whereas cytomegalovirus (CMV) infection was demonstrated in 40 patients (16%).
  
  
  CONCLUSIONS
  Immunosuppressive therapy, necessary to avoid acute and chronic rejection, exposes patients to a higher rate of infectious complications. The immunosuppressive protocols led to a relatively low incidence of infectious complications, mainly of little clinical significance. The highest incidence was evident by the sixth month after transplantation, when the immunosuppressive regimen exercised its most depressive effects on patient immune systems.
authors.affiliation: Department of Surgery, Transplantation and Advanced Technologies-Organ Transplant Unit, University Hospital of Catania, Catania, Italy. veroux@unict.it
authors.forename: M
authors.initials: M
authors.lastname: Veroux
authors.forename: G
authors.initials: G
authors.lastname: Giuffrida
authors.forename: D
authors.initials: D
authors.lastname: Corona
authors.forename: M
authors.initials: M
authors.lastname: Gagliano
authors.forename: V
authors.initials: V
authors.lastname: Scriffignano
authors.forename: D
authors.initials: D
authors.lastname: Vizcarra
authors.forename: T
authors.initials: T
authors.lastname: Tallarita
authors.forename: D
authors.initials: D
authors.lastname: Zerbo
authors.forename: C
authors.initials: C
authors.lastname: Virgilio
authors.forename: A
authors.initials: A
authors.lastname: Sciacca
authors.forename: D
authors.initials: D
authors.lastname: Cappello
authors.forename: S
authors.initials: S
authors.lastname: Stefani
authors.forename: P
authors.initials: P
authors.lastname: Veroux
mesh_terms: D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000453:epidemiology; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007239:Infections / Q000453:epidemiology*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008875:Middle Aged; D011014:Pneumonia / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology* / Q000382:microbiology / Q000821:virology; D012189:Retrospective Studies; D013530:Surgical Wound Infection / Q000453:epidemiology; D014184:Transplantation, Homologous; D014552:Urinary Tract Infections / Q000453:epidemiology
chemical_list: D007166:Immunosuppressive Agents